B.R.A.I.N. Biotechnology Research and Information Network AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom.
High growth potential with adequate balance sheet.
Share Price & News
How has B.R.A.I.N. Biotechnology Research and Information Network's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BNN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BNN underperformed the German Chemicals industry which returned -29.3% over the past year.
Return vs Market: BNN underperformed the German Market which returned -14.1% over the past year.
Price Volatility Vs. Market
How volatile is B.R.A.I.N. Biotechnology Research and Information Network's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StVolatility 101: Should B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Shares Have Dropped 42%?
2 months ago | Simply Wall StIs B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Using Debt In A Risky Way?
3 months ago | Simply Wall StWhen Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Become Profitable?
Is B.R.A.I.N. Biotechnology Research and Information Network undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BNN (€6.08) is trading below our estimate of fair value (€24.07)
Significantly Below Fair Value: BNN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BNN is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.
PE vs Market: BNN is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BNN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BNN is overvalued based on its PB Ratio (7.2x) compared to the DE Chemicals industry average (1.2x).
How is B.R.A.I.N. Biotechnology Research and Information Network forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BNN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: BNN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BNN's is expected to become profitable in the next 3 years.
Revenue vs Market: BNN's revenue (13.8% per year) is forecast to grow faster than the German market (4% per year).
High Growth Revenue: BNN's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BNN's Return on Equity is forecast to be very high in 3 years time (132.3%).
How has B.R.A.I.N. Biotechnology Research and Information Network performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BNN is currently unprofitable.
Growing Profit Margin: BNN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BNN is unprofitable, but has reduced losses over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare BNN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BNN is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (1.2%).
Return on Equity
High ROE: BNN has a negative Return on Equity (-75.3%), as it is currently unprofitable.
How is B.R.A.I.N. Biotechnology Research and Information Network's financial position?
Financial Position Analysis
Short Term Liabilities: BNN's short term assets (€28.1M) exceed its short term liabilities (€14.5M).
Long Term Liabilities: BNN's short term assets (€28.1M) do not cover its long term liabilities (€40.7M).
Debt to Equity History and Analysis
Debt Level: BNN is debt free.
Reducing Debt: BNN has no debt compared to 5 years ago when its debt to equity ratio was 51.7%.
Inventory Level: BNN has a high level of physical assets or inventory.
Debt Coverage by Assets: BNN's debt is not covered by short term assets (assets are -20.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BNN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BNN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is B.R.A.I.N. Biotechnology Research and Information Network's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BNN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BNN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BNN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BNN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BNN's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Adriaan Moelker, also known as Aryan, has been Chairman of the Management Board and Chief Executive Officer of B.R.A.I.N. Biotechnology Research and Information Network AG since February 1, 2020. Mr. M ...
|CFO & Member of Management Board||1.17yrs||€380.60k||no data|
|Chief Business Officer & Member of Management Board||1.42yrs||€389.60k||no data|
|Chairman of the Management Board & CEO||0.083yr||no data||no data|
|Co-Founder||no data||no data||no data|
|Executive VP & Head Industrial BioSolutions Business Unit||no data||no data||no data|
|Executive VP & Head of Technology Unit - Producer Strain Development||no data||no data||no data|
|Head of Organisation & Processes Unit||no data||no data||no data|
|Executive VP and Head of Research & Development||no data||no data||no data|
|Unit Head of Finance & Controlling||2.17yrs||no data||no data|
Experienced Management: BNN's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
|Independent Chairman of the Supervisory Board||1yr||€70.00k||no data|
|Independent Member of Supervisory Board||1yr||€27.00k||no data|
|Member of Supervisory Board||1yr||€14.00k||no data|
|Deputy Chairwoman of the Supervisory Board||0.17yr||€41.00k||no data|
Experienced Board: BNN's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
B.R.A.I.N. Biotechnology Research and Information Network AG's company bio, employee growth, exchange listings and data sources
- Name: B.R.A.I.N. Biotechnology Research and Information Network AG
- Ticker: BNN
- Exchange: XTRA
- Founded: 1993
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: €109.779m
- Shares outstanding: 18.06m
- Website: https://www.brain-biotech.de
Number of Employees
- B.R.A.I.N. Biotechnology Research and Information Network AG
- Darmstadter Strasse 34-36
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BNN||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jan 2016|
|BNN||XTRA (XETRA Trading Platform)||Yes||Ordinary Shares||DE||EUR||Jan 2016|
|0RFI||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Jan 2016|
|BNND||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Jan 2016|
B.R.A.I.N. Biotechnology Research and Information Network AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. It operates through BioScience and BioIndustrial segments. The company identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and natural-source substances for product development in the food, animal feed, skincare, cosmetics, and chemical industries, as well as to stabilize paints, lacquers, and other household products; It also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations and lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of climate gas CO2 as an industrial raw material for bioplastics, and extraction of precious and rare earth metals. The company has a strategic partnership with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. B.R.A.I.N. Biotechnology Research and Information Network AG was founded in 1993 and is headquartered in Zwingenberg, Germany.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/28 23:49|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.